GlassScriptPhysician profile
Bryce Allen Somer
NPI 1508285495
$7,885.96
in general payments reported to CMS, 2019-2025
46 companies · $1,663 in 2025
The $1,663 reported for 2025 was more than what 91% of Internal Medicine providers received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $958 · 2020: $778 · 2021: $780 · 2022: $832 · 2023: $1,463 · 2024: $1,413 · 2025: $1,663.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $4,528 · Education: $11.56.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $4,527.58 |
| Education | $11.56 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $1,056.81 | 2019-2025 | Rybelsus, Ozempic, Wegovy |
| Pfizer INC. | $967.16 | 2019-2025 | |
| Astrazeneca Pharmaceuticals LP | $667.21 | 2019-2025 | Farxiga, Breztri, Airsupra |
| Amgen INC. | $555.61 | 2019-2025 | Repatha, Otezla, Otezla |
| Lilly USA, LLC | $538.80 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Merck Sharp & Dohme LLC | $473.22 | 2019-2025 | Verquvo, Belsomra, Gardasil 9 |
| Abbvie INC. | $453.52 | 2019-2025 | Vraylar, Synthroid, Qulipta |
| Glaxosmithkline, LLC. | $365.14 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Otsuka America Pharmaceutical, INC. | $285.43 | 2022-2025 | Rexulti |
| Takeda Pharmaceuticals U.S.A., INC. | $278.64 | 2019-2023 | Trintellix |
| Bayer Healthcare Pharmaceuticals INC. | $276.13 | 2021-2025 | |
| Exact Sciences Corporation | $269.70 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Novartis Pharmaceuticals Corporation | $261.73 | 2020-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $113.69 | 2019-2025 | Xifaxan |
| Kowa Pharmaceuticals America, INC. | $100.95 | 2019-2021 |
Show all 46 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Bryce Somer listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.